2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2 · Dec 24, 2024 · US
Method for preparing thienopyrimidine compound and intermediates used therein
US10160770B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10160770-B2 |
| Application number | US-201816025784-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 2, 2018 |
| Priority date | Dec 30, 2014 |
| Publication date | Dec 25, 2018 |
| Grant date | Dec 25, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the following Formula 2 or a salt thereof: 2. A compound of the following Formula 3 or a salt thereof: 3. A compound of the following Formula 4 or a salt thereof: wherein L is and R 1 is C 1-10 alkyl or benzyl. 4. A method for preparing a compound of the following Formula 3 or a salt thereof, comprising the step of allowing a compound of the following Formula 4 or a salt thereof to react with a compound of the following Formula 9 or a salt thereof and an organic acid: wherein L is or halogen and R 1 is C 1-10 alkyl or benzyl.
Assignees
Inventors
Classifications
- C07D495/04Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10160770B2 cover?
- A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.
- Who is the assignee on this patent?
- Hanmi Pharm Ind Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).